Diligence memo · auto-generated · as of July 3, 2026
Kaneh Bosm Biotechnology Inc.
Kaneh Bosm Biotechnology Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Kaneh Bosm Biotechnology Inc. operates in Biotech, based in VANCOUVER.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kaneh Bosm Biotechnology Inc. has raised $11M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.9M on 2018-06-12.
Most recent recorded round closed around 2018-06-28.
Valuation (modeled)modeled
Provath models Kaneh Bosm Biotechnology Inc. at approximately $90M (range $2.7M–$491M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.39× the median modeled value of Series A Biotech companies in 2016–2018 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 0 months.
Last raise 8.0 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotech peers (233 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Montlake Bioscience Inc., Impact Genomics, Inc., Transplant Genomics Inc., Benchling, Inc., Franklin BioScience - Penn LLC.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.